Jasper Therapeutics, Inc. (JSPR)

NASDAQ: JSPR · USD

$0.52

+0.00 (+0.9%)· Recorded snapshot

Market cap	17.4M
Shares out	33.3M
Volume	365,893
Beta	3.17

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Market cap: 17.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

S&P 500+0.8%

Nasdaq Composite-1.0%

Dow Jones Industrial Average+1.9%

Russell 2000+0.3%

All JSPR indicators

Market & fundamental data

Available fields

145

Groups with data

Currency

USD

Showing 145 of 145 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001788028
Company name	Jasper Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	471871202
Earnings date	2026-11-09
Earnings time	bmo
Employees	22
Employees change	-42
Employees growth	-65.63%
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US4718712023
Last 10-K release date	2026-03-30
Last earnings date	2026-08-14
Last refreshed	2026-10-28
Last stock split date	2024-01-04
Last stock split type	Reverse
Market cap	$17.4M
Market cap category	Nano-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$0.52
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	JSPR
U.S. state	California
Website	https://jaspertx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
FCF yield	-338.47%
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROA (5Y)	-57.44%
ROE (5Y)	-118.9%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	5
Net income growth quarters	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$561,000
FCF per share	$-1.81
Financing cash flow	$28.1M
Free cash flow	$-60.3M
Free cash flow minus SBC	$-64.6M
Investing cash flow	$80,000
Net cash flow	$-32.2M
Operating cash flow minus SBC	$-64.6M
Stock-based compensation	$4.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Net cash growth	-81.14%
Piotroski F-Score	0
Property, plant and equipment	$188,000
WACC	21.66%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$11.6M
Current liabilities	$7.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-71.73%
Dividend yield	0%
Shareholder yield	-71.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$0.69
1D price change	0.89%
1M price change	-14.05%
1M total return	-14.05%
1W price change	4.72%
1W total return	4.72%
1Y price change	-77.53%
1Y return CAGR	-77.56%
1Y total return	-77.53%
20-day SMA	$0.53
200-day SMA	$0.86
3M price change	-24.6%
3M total return	-24.6%
3Y price change	-92.42%
3Y return CAGR	-57.68%
3Y total return	-92.42%
50-day SMA	$0.61
50-day SMA vs 200-day SMA	50under200
52-week high	$2.52
52-week high date	2025-10-29
52-week low	$0.32
52-week low date	2026-06-29
5Y price change	-99.48%
5Y return CAGR	-65.13%
5Y total return	-99.48%
6M price change	-43.7%
6M total return	-43.7%
All-time high	$188.80
All-time high date	2021-10-15
All-time low	$0.32
All-time low date	2026-06-29
Average true range (ATR)	$0.05
Average volume	387.9K
Beta (1Y)	3.11
Beta (2Y)	2.67
Beta (5Y)	3.17
Change from 52-week high	-79.23%
Change from 52-week low	66.14%
Change from all-time high	-99.72%
Change from all-time low	66.14%
Change from open	-0.87%
Day's gap	1.77%
Dollar volume	$191,545
High price	$0.54
Low price	$0.52
Monthly RSI	31.28
Open price	$0.53
Position in 52-week range	0%
Premarket change	-0.52%
Premarket close	$0.52
Premarket price	$0.52
Premarket volume	619
Previous close	$0.52
Price vs 150-day SMA	-24.48%
Price vs 20-day SMA	-1.36%
Price vs 200-day SMA	-39.29%
Price vs 50-day SMA	-14.07%
Relative volume	0.94
RSI	44.89
Sharpe ratio	-0.95
Sharpe ratio (3Y)	-0.33
Sharpe ratio (5Y)	-0.02
Sortino ratio	-1.21
Sortino ratio (3Y)	-0.37
Sortino ratio (5Y)	-0.02
Volume	365.9K
Weekly RSI	37.13
YTD price change	-71.39%
YTD total return	-71.39%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	30.2M
Float percentage	90.68%
Shares change (QoQ)	0.09%
Shares change (YoY)	71.73%
Shares held by insiders	2.09%
Shares held by institutions	5.34%
Shares outstanding	33.3M
Short % of float	21.46%
Short % of shares	19.46%
Short ratio	16.2 days

Deeper analysis on JSPR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this JSPR report

Is a complete JSPR research report available?

No complete published report is available for Jasper Therapeutics, Inc. (JSPR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Jasper Therapeutics, Inc. (JSPR)

Price

Financial snapshot

Fair-value bridge

Latest news · JSPR

Valuation

Trading

Next earnings

Sector percentile context

All JSPR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on JSPR

Frequently asked questions